Britannia Life Sciences Inc
F:L020
Balance Sheet
Balance Sheet Decomposition
Britannia Life Sciences Inc
Britannia Life Sciences Inc
Balance Sheet
Britannia Life Sciences Inc
| Nov-2015 | Nov-2016 | Nov-2017 | Nov-2018 | Nov-2019 | Nov-2020 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
1
|
4
|
0
|
0
|
2
|
3
|
1
|
8
|
|
| Cash |
0
|
0
|
1
|
4
|
0
|
0
|
2
|
3
|
1
|
8
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
2
|
|
| Total Current Assets |
0
|
0
|
1
|
5
|
2
|
0
|
3
|
4
|
3
|
10
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Intangible Assets |
0
|
0
|
2
|
0
|
0
|
0
|
17
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
17
|
18
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
17
|
18
|
0
|
|
| Total Assets |
0
N/A
|
0
+20%
|
3
+611%
|
6
+79%
|
3
-44%
|
0
-92%
|
21
+8 094%
|
24
+12%
|
22
-5%
|
12
-48%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
2
|
2
|
3
|
3
|
3
|
3
|
3
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
0
|
0
|
0
|
10
|
11
|
0
|
2
|
2
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
| Total Current Liabilities |
3
|
1
|
1
|
3
|
12
|
13
|
8
|
5
|
11
|
4
|
|
| Long-Term Debt |
0
|
2
|
2
|
5
|
1
|
0
|
0
|
6
|
5
|
2
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
0
|
|
| Other Liabilities |
0
|
1
|
1
|
2
|
0
|
0
|
7
|
1
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
4
+27%
|
4
-2%
|
9
+137%
|
13
+45%
|
13
+2%
|
20
+47%
|
17
-16%
|
20
+20%
|
5
-73%
|
|
| Equity | |||||||||||
| Common Stock |
15
|
15
|
19
|
25
|
25
|
25
|
17
|
17
|
17
|
17
|
|
| Retained Earnings |
21
|
23
|
25
|
34
|
42
|
47
|
14
|
9
|
17
|
13
|
|
| Additional Paid In Capital |
4
|
5
|
5
|
6
|
7
|
9
|
0
|
0
|
3
|
3
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Total Equity |
3
N/A
|
3
-28%
|
1
+80%
|
3
-400%
|
10
-189%
|
13
-31%
|
1
N/A
|
7
+419%
|
2
-65%
|
6
+158%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
+20%
|
3
+611%
|
6
+79%
|
3
-44%
|
0
-92%
|
21
+8 094%
|
24
+12%
|
22
-5%
|
12
-48%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
3
|
6
|
6
|
6
|
162
|
162
|
162
|
162
|
|